

**Position Statement:** *To be adhered to in line with the CCG Prescribing Policy*

Treatment	<b>Botulinum Toxin Type A</b>
<b>Commissioning position</b>	<p>The use of botulinum toxin type A is <b>supported</b> in the following indications for people registered with a Herefordshire or Worcestershire GP or resident within Herefordshire or Worcestershire and not currently registered with any GP:</p> <ul style="list-style-type: none"> <li>• Anal fissures, after three months with standard treatment for chronic anal fissures.</li> <li>• Blepharospasm and hemifacial spasm.</li> <li>• Probable contracture of joint in multiple sclerosis, in conjunction with prolonged stretching modalities.</li> <li>• Focal dystonia, where other measures are inappropriate or ineffective.</li> <li>• Focal spasticity in patients with upper motor neurone syndrome, caused by cerebral palsy, stroke, acquired brain injury, multiple sclerosis, spinal cord injuries and neurodegenerative disease, where other measures are inappropriate or ineffective.</li> <li>• Idiopathic cervical dystonia (spasmodic torticollis).</li> <li>• Prophylaxis of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) that has not responded to at least three prior pharmacological prophylaxis therapies, and whose condition is appropriately managed for medication overuse; (i.e. in line with <a href="#">NICE TA 260</a>).</li> <li>• Refractory detrusor overactivity, in line with local care pathway and <a href="#">NICE guideline NG123</a>, where conservative therapy (including overactive bladder drug therapy) has failed.</li> <li>• Sialorrhoea (excessive salivary drooling), when all other treatments have failed, in line with local care pathway and <a href="#">NICE TA 605</a>.</li> </ul> <p>Where the use of botulinum toxin type A is used to treat an indication outside of the manufacturer's marketing authorisation, clinicians and patients should be aware of the particular governance requirements, including consent, for using drugs off-label.</p> <p>Botulinum toxin type A is <b>not routinely commissioned</b> in the following indications:</p> <ul style="list-style-type: none"> <li>• Canthal lines (crow's feet) and glabellar (frown) lines</li> <li>• Hyperhidrosis</li> <li>• Any other indication not listed as supported above</li> </ul> <p>For patients with conditions which are not routinely commissioned, as indicated above, requests will continue to be considered by the Clinical Commissioning Group through the individual funding request (IFR) process, if there is evidence that the patient is considered to have clinically exceptional circumstances to any other patient experiencing the same condition within Herefordshire and Worcestershire. Requests to commission the use of botulinum toxin as an option to treat other indications, where a known cohort of patients can be identified, should be processed by application to the Herefordshire &amp; Worcestershire Medicines and Prescribing Committee.</p>
<b>Approved Date for Review</b>	<p>March 2020 March 2023 <i>or sooner if additional national guidance and/or published evidence is made available</i></p>